research use only

Zandelisib PI3K inhibitor

Name: Zandelisib
Brand: Selleck Chemicals
SKU: S3575
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S3575

Zandelisib(ME-401; PWT-143) is an orally bioavailable inhibitor of the phosphatidylinositide 3-kinase (PI3K). It selectively inhibits the delta isoform of PI3K (p110δ) and prevents the activation of the PI3K/AKT signaling pathway with an IC50 of 3.5 nM. It functions as an antineoplastic agent.

Chemical Structure

Molecular Weight: 576.68

Jump to

Quality Control

Batch: S357501 DMSO]13 mg/mL]false]Ethanol]3 mg/mL]false]Water]Insoluble]false Purity: 99.44%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.44

Related Targets	Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PI4K PP2A
Other PI3K Inhibitors	GDC-0077 (Inavolisib) SAR405 Quercetin (Sophoretin) LY294002 XL147 analogue Tersolisib (STX-478) Buparlisib (BKM120) 740 Y-P (PDGFR 740Y-P) GO-203 TFA Eganelisib (IPI-549)

Solubility

In vitro
Batch:

DMSO : 13 mg/mL (22.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.650mg/ml (1.13mM)	Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.300mg/ml (0.52mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	576.68	Formula	C₃₁H₃₈F₂N₈O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1401436-95-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	PI3Kδ 3.5 nM
References	[1] https://patents.google.com/patent/WO2014055647A1

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2023-07-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05604417	WITHDRAWN	Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma	Jacob Soumerai, MD	2023-01	PHASE1; PHASE2
NCT03768505	TERMINATED	Follicular Lymphoma (FL); Non Hodgkin Lymphoma; Marginal Zone Lymphoma	MEI Pharma, Inc.	2019-06-25	PHASE2
NCT04745832	TERMINATED	Follicular Lymphoma (FL); Non Hodgkin Lymphoma; Marginal Zone Lymphoma	MEI Pharma, Inc.	2021-08-13	PHASE3
NCT05209308	WITHDRAWN	CLL	MEI Pharma, Inc.	2022-11-22	PHASE2
NCT04533581	Active not recruiting	Indolent B-cell Non-Hodgkin''s Lymphoma	Kyowa Kirin Co. Ltd.	2020-09-17	Phase 2
NCT03768505	Terminated	Follicular Lymphoma (FL)\|Non Hodgkin Lymphoma\|Marginal Zone Lymphoma	MEI Pharma Inc.	2019-06-25	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):